Alnylam Short Term Coverage Ratios from 2010 to 2025

ALNY Stock  USD 246.75  9.65  4.07%   
Alnylam Pharmaceuticals Short Term Coverage Ratios yearly trend continues to be fairly stable with very little volatility. Short Term Coverage Ratios is likely to outpace its year average in 2025. During the period from 2010 to 2025, Alnylam Pharmaceuticals Short Term Coverage Ratios regression line of annual values had significance of  0 and arithmetic mean of (31.89). View All Fundamentals
 
Short Term Coverage Ratios  
First Reported
2010-12-31
Previous Quarter
1.7
Current Value
1.79
Quarterly Volatility
20.13147718
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 59.5 M, Interest Expense of 149 M or Other Operating Expenses of 2.5 B, as well as many indicators such as Price To Sales Ratio of 12.79, Dividend Yield of 0.0 or PTB Ratio of 474. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Short Term Coverage Ratios Growth Pattern

Below is the plot of the Short Term Coverage Ratios of Alnylam Pharmaceuticals over the last few years. It is Alnylam Pharmaceuticals' Short Term Coverage Ratios historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Short Term Coverage Ratios10 Years Trend
Slightly volatile
   Short Term Coverage Ratios   
       Timeline  

Alnylam Short Term Coverage Ratios Regression Statistics

Arithmetic Mean(31.89)
Coefficient Of Variation(63.14)
Mean Deviation17.87
Median(46.18)
Standard Deviation20.13
Sample Variance405.28
Range48.0762
R-Value0.70
Mean Square Error219.95
R-Squared0.49
Significance0
Slope2.97
Total Sum of Squares6,079

Alnylam Short Term Coverage Ratios History

2025 1.79
2024 1.7
2023 1.89
2022 -13.43
2021 -17.31
2011 -46.18
2010 -22.99

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Short Term Coverage Ratios, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short Term Coverage Ratios 1.70  1.79 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.